Skip to content
OpenCapital
Get started

Johnson & Johnson JNJ OTHER IMMUNOLOGY — Sales to customers (Note 9)

Other product segments

ELECTROPHYSIOLOGY
$5.63B+7.0%
DARZALEX
$3.96B+22.5%
Other
$2.9B+2.1%
SPINE,SPORTS & OTHER
$2.85B-2.5%
Tremfya
$1.61B+68.2%
GENERAL
$1.39B+4.9%
ADVANCED
$1.12B+4.7%
INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA
$1.04B+15.0%
CONTACT LENSES / OTHER
$969M+5.4%
ERLEADA
$949M+23.1%
TRAUMA
$833M+7.9%
SPINE & OTHER
$694M+3.4%
IMBRUVICA
$660M-6.9%
STELARA
$656M-59.6%
SIMPONI / SIMPONI ARIA
$647M-1.8%
XARELTO
$642M-7.0%
OPSUMIT/OPSYNVI
$606M+16.1%
CARVYKTI
$597M+61.8%
UPTRAVI
$483M+7.1%
SPRAVATO
$468M+46.3%
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
$443M+9.9%
HIPS
$436M+6.6%
Remicade
$422M-9.6%
KNEES
$420M+8.0%
EDURANT/rilpivirine
$409M+14.2%
other cardiovascular
$397M+4.5%
SURGICAL
$396M+9.7%
CAPLYTA
$270M—
OTHER NEUROSCIENCE
$262M-5.4%
RYBREVANT + LAZCLUZE
$257M+82.3%
Tecvayli
$202M+33.8%
Other Oncology
$192M-10.3%
TALVEY
$152M+76.7%
CONCERTA/Methylphenidate
$136M-8.1%
OTHER INFECTIOUS DISEASES
$37M-9.8%

Similar metrics at other companies

Eli Lilly logo
LLYOther immunology — Revenue
$470M+44.2%
Eli Lilly logo
LLYImmunology — Revenue
$1.2B+10.6%
Arcus Biosciences logo
RCUSOther — Total revenues
$2M—
Schrodinger logo
SDGROncology, Neurology, and Immunology Product — Total revenues
$700K+16.7%
SRT
SRTAOther Clinical — Revenue
$9.95M—
Eli Lilly logo
LLYOther oncology — Revenue
$966M+22.4%

Other financials

Income statement

See full
Revenue$24.1B+9.9%
Gross profit$16.0B+9.8%
Operating income$6.3B+2.3%
Net income$5.2B-52.4%
EPS (diluted)$2.14-52.9%

Balance sheet

See full
Cash & equivalents$21.7B-43.6%
Total debt$55.0B+5.2%
Total equity$81.2B+3.9%
Total assets$200.89B+3.7%

Cash flow

See full
Operating cash flow$2.5B-39.8%
CapEx$1.0B+31.9%
Free cash flow$1.5B-56.6%

Valuation

See full
Market cap$623.71B+66.9%
Enterprise value$657.01B+61.9%
P/E29.6×+13.2×
P/S6.5×+2.3×

Profitability

See full
Gross margin67.8%-0.5pp
Operating margin26.4%+2.8pp
Net margin21.8%-2.6pp
FCF margin18.5%-4.3pp

Returns & leverage

See full
Return on equity26.4%-3.0pp
Debt / equity0.7×0.0×
Current ratio1×-0.2×

Where this comes from

Reported directly by Johnson & Johnson in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Johnson & Johnson’s 10-Q, filed April 22, 2026, on SEC EDGAR. View the filing →

Ask your AI about Johnson & Johnson's other immunology — sales to customers (note 9).

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Johnson & Johnson's OTHER IMMUNOLOGY — sales to customers (note 9)?
Johnson & Johnson (JNJ) reported OTHER IMMUNOLOGY — sales to customers (note 9) of $46M in Q1 2026.
How has Johnson & Johnson's OTHER IMMUNOLOGY — sales to customers (note 9) changed year-over-year?
Johnson & Johnson's OTHER IMMUNOLOGY — sales to customers (note 9) increased by 4500.0% year-over-year, from $1M to $46M.
What is the long-term trend for Johnson & Johnson's OTHER IMMUNOLOGY — sales to customers (note 9)?
Over 4 years (2021 to 2025), Johnson & Johnson's OTHER IMMUNOLOGY — sales to customers (note 9) has grown at a 26.3% compound annual growth rate (CAGR), from $24M to $61M.
What does OTHER IMMUNOLOGY — sales to customers (note 9) mean?
This metric represents the net revenue generated from the sale of pharmaceutical products within the 'Other Immunology' portfolio. It captures the financial performance of specialized immunological therapies that fall outside of the company's primary or flagship immunology product lines. This segment is critical for assessing the diversification and growth potential of the company's broader autoimmune and inflammatory disease treatment pipeline.